Mezagitamab Biosimilar – Anti-CD38 mAb – Research Grade from ProteoGenix; catalogue PX-TA1543; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Mezagitamab Biosimilar, also known as Anti-CD38 mAb, is a research grade monoclonal antibody that has been developed as a potential therapeutic agent for various diseases. This antibody specifically targets CD38, a cell surface protein that is involved in several biological processes, making it a promising therapeutic target.
Mezagitamab Biosimilar is a recombinant humanized monoclonal antibody that is produced using advanced biotechnology techniques. It is composed of two heavy chains and two light chains, which are connected by disulfide bonds. The antibody has a molecular weight of approximately 150 kDa.
Mezagitamab Biosimilar works by binding to CD38 on the surface of cells. CD38 is a transmembrane glycoprotein that is expressed on various cell types, including immune cells, plasma cells, and some cancer cells. When Mezagitamab Biosimilar binds to CD38, it triggers a series of events that ultimately lead to the destruction of the target cell.
One of the main mechanisms of action of Mezagitamab Biosimilar is the activation of the immune response. CD38 is involved in the regulation of immune cell function, and its overexpression has been linked to immune dysfunction in various diseases. By targeting and binding to CD38, Mezagitamab Biosimilar can modulate the activity of immune cells, leading to enhanced immune response against diseased cells.
Mezagitamab Biosimilar also induces apoptosis, or programmed cell death, in cells that express high levels of CD38. This mechanism is particularly relevant in cancer cells, as they often evade apoptosis and continue to grow uncontrollably. By binding to CD38, Mezagitamab Biosimilar activates signaling pathways that promote apoptosis, effectively killing cancer cells.
Mezagitamab Biosimilar has shown promising results in preclinical studies for the treatment of various diseases, including multiple myeloma, chronic lymphocytic leukemia, and autoimmune diseases.
cancer that affects plasma cells. CD38 is highly expressed on the surface of multiple myeloma cells, making it an ideal target for Mezagitamab Biosimilar. In preclinical studies, Mezagitamab Biosimilar has shown significant anti-tumor activity and prolonged survival in animal models of multiple myeloma.
Chronic lymphocytic leukemia (CLL) is a type of cancer that affects white blood cells. CD38 is expressed at high levels on the surface of CLL cells, making it a potential therapeutic target. Mezagitamab Biosimilar has shown promising results in preclinical studies, with significant reduction in tumor burden and improved survival rates in animal models of CLL.
CD38 is involved in the regulation of immune cell function, and its overexpression has been linked to autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. Mezagitamab Biosimilar has shown potential in preclinical studies for the treatment of these diseases, by modulating the activity of immune cells and reducing inflammation.
Mezagitamab Biosimilar, also known as Anti-CD38 mAb, is a research grade monoclonal antibody that specifically targets CD38. Its unique mechanism of action, which involves activation of the immune response and induction of apoptosis, makes it a promising therapeutic agent for various diseases. With ongoing research and clinical trials, Mezagitamab Biosimilar has the potential to improve the treatment options for patients with multiple myeloma, chronic lymphocytic leukemia, and autoimmune diseases.
ProteoGenix catalogue number PX-TA1543. For research use only.
Target: Mezagitamab Biosimilar – Anti-CD38 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: Mammalian cells; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Mezagitamab Biosimilar – Anti-CD38 mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
